Immunotherapy

A powerful approach to cancer therapy involves modifying the patient's immune cells or cancer cells in order to enhance the immune response against them. Such modifications may be accomplished by inserting appropriate genetic information or antigen into the cells. The safety and efficiency of such a procedure depends in large part upon the method chosen for gene delivery into the cancer cells. The shortcomings of available technologies to deliver genetic information to target immune or cells has prompted leading Academic translational medical centers and Commercial Partners to turned to MaxCyte's gene delivery technology to expedite taking potential therapeutics from the bench to the clinic.


Click to Enlarge
  • MaxCyte Enhances Value of DC Vaccines [Click Here] (also available in PDF)
  • Electroloading Dendritic Cells J. Immunotherapy [Click Here]
"MaxCyte provides us with a rapid, sterile system that successfully transfect CLL cells with a high level of viability and efficiency to create this autologous immunotherapeutic approach. We were delighted MaxCyte's solution allowed us to overcome hurdles that were impeding our efforts to develop an immunotherapy for cancer patients." -Dr. Malcolm K. Brenner, Director and Professor, Baylor College of Medicine -Immunotherapy Case Study [Click Here]